Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by subaru1on Jul 08, 2024 12:16pm
109 Views
Post# 36122906

Last calendar about rescheduling from 1 to 3

Last calendar about rescheduling from 1 to 3

Timeline for Implementation

Key dates include:

  • May 21, 2024: Publication of the proposed rescheduling draft ruling (PRDR) in the Federal Register and the start of a 60-day public comment period.
  • June 21, 2024: Deadline for interested parties to request a hearing.
  • July 20, 2024: End of the public comment period.
  • August 20, 2024 (or September 20, 2024): Expected publication of the final ruling. The final ruling becomes effective 30 days after publication, potentially around September 20, 2024.

Potential Risks And Wild Cards

Zuanic identifies several wild cards that could influence the process and outcomes:

  • Scope of Cole Memo II: Whether it includes SAFE banking language, provides a safe harbor for U.S. exchanges to list plant-touching stocks, and addresses FinCEN-related matters.
  • Legal Challenges: Judicial challenges are expected, but legal scholar Shane Pennington considers a stay unlikely.
  • Political Factors: Statements from Donald Trump and their impact on public opinion.

Sector And Stock Impacts

The rescheduling news has broader implications for the cannabis sector.

Canadian licensed producers (LPs) like Canopy Growth Corporation (NASDAQ:CGC) and SNDL (NASDAQ:SNDL) might need to form partnerships with U.S. companies to capitalize on the changing landscape.

 
 

 

Companies such as Tilray Brands (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), and others are under scrutiny for their strategic moves in response to the evolving regulatory environment.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse